Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:25:07 EDT Thu 20 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:NBIX - NEUROCRINE BIOSCIENCES INC - https://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q0.1109.50·131.340.1110.07-0.24-0.2870.695,27512,752109.86  111.25  109.83157.9799  105.17519:28:4308:3015 min RT 2¢

Recent Trades - Last 10 of 12752
Time ETExPriceChangeVolume
19:28:43Q112.662.353
16:43:06Q110.07-0.24416
16:20:00Q110.07-0.247
16:05:11Q110.07-0.241
16:05:11Q110.07-0.241
16:05:09Q110.07-0.241
16:01:48Q110.07-0.244
16:01:38Q110.07-0.2472
16:01:37Q110.07-0.24649
16:01:20Q110.07-0.247,112

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-20 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA(TM) (valbenazine) Capsules
2025-03-17 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New KINECT(TM)-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA(TM) (valbenazine) Capsules
2025-03-11 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
2025-03-05 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
2025-02-27 16:05U:NBIXNews ReleaseNeurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO(TM) Study for INGREZZA(TM) (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
2025-02-25 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at Upcoming Investor Conferences in March
2025-02-21 08:00U:NBIXNews ReleaseNeurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
2025-02-06 16:01U:NBIXNews ReleaseNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
2025-01-30 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
2025-01-28 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
2025-01-27 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
2025-01-23 16:05U:NBIXNews ReleaseAndrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
2025-01-21 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
2025-01-08 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
2025-01-06 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-20 08:00U:NBIXNews ReleaseNeurocrine Biosciences Announces Commercial Availability of CRENESSITY(TM) (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
2024-12-13 18:55U:NBIXNews ReleaseNeurocrine Biosciences Announces FDA Approval of CRENESSITY(TM) (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
2024-11-26 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Investor Conferences in December
2024-11-07 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New KINECT(TM)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(TM) (valbenazine) Capsules
2024-11-05 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Investor Conferences in November